These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22291137)

  • 1. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
    Patel AG; De Lorenzo SB; Flatten KS; Poirier GG; Kaufmann SH
    Clin Cancer Res; 2012 Mar; 18(6):1655-62. PubMed ID: 22291137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
    Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
    J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
    Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
    Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
    Pierce A; McGowan PM; Cotter M; Mullooly M; O'Donovan N; Rani S; O'Driscoll L; Crown J; Duffy MJ
    Cancer Biol Ther; 2013 Jun; 14(6):537-45. PubMed ID: 23760496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
    J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
    Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
    J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
    Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
    Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
    Norris RE; Adamson PC; Nguyen VT; Fox E
    Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
    To C; Kim EH; Royce DB; Williams CR; Collins RM; Risingsong R; Sporn MB; Liby KT
    Cancer Prev Res (Phila); 2014 Jul; 7(7):698-707. PubMed ID: 24817481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
    Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
    Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
    Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
    Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
    Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG
    Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
    Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
    Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
    Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
    Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.